PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930062
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930062
Pharmacovigilance Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
Growth Factors of pharmacovigilance (PV) Market
The global pharmacovigilance (PV) market was valued at USD 9.35 billion in 2025 and is projected to reach USD 10.54 billion in 2026, eventually expanding to USD 31.56 billion by 2034, reflecting a CAGR of 14.69% during the forecast period. North America dominated the market in 2025 with a 40.84% share, driven by a strong pharmaceutical industry, high healthcare expenditure, advanced infrastructure, and a stringent regulatory environment. Key players in the market include IQVIA Inc., Laboratory Corporation of America Holdings, Accenture, Cognizant, Ergomed Group, Parexel International Corporation, ICON plc., and Quanticate, focusing on technological innovations, AI adoption, partnerships, and geographic expansion.
Pharmacovigilance involves monitoring, assessing, and preventing adverse drug reactions (ADRs) to ensure the safety and efficacy of medications. It spans preclinical, clinical, and post-marketing stages, collecting and analyzing data from healthcare providers, patients, and regulatory authorities. Increasing ADR reporting, rising drug launches, and investments in clinical trials are driving demand for PV services and software globally. For example, Australia reported 125,873 adverse event notifications in 2021-22, highlighting the need for robust drug safety monitoring.
Market Drivers
Rising ADR Awareness and Public Initiatives: Growing awareness among healthcare providers, patients, and governments has significantly fueled the market. Campaigns such as Uppsala Monitoring Centre's annual social media initiatives and MedSafety Week in 2023 educate the public about ADR reporting, leading to increased adoption of PV services.
Outsourcing Trend by Pharmaceutical Companies: Many pharmaceutical firms prefer outsourcing PV services to specialized providers to streamline operations, reduce costs, and access expert solutions. In 2024, ProPharma Group acquired Clinres Farmacija to expand post-marketing regulatory and PV services in Europe, reflecting this trend. Outsourcing enhances flexibility, regulatory compliance, and efficiency in monitoring marketed drugs.
Technological Innovations and AI Integration: Artificial intelligence is increasingly applied in PV for faster detection and assessment of adverse events. For instance, in April 2023, Parexel International collaborated with Partex to leverage AI-powered solutions in drug discovery and development, improving regulatory decision-making and workflow efficiency. AI adoption also helps PV professionals focus on value-added tasks, enhancing the overall efficacy of drug safety monitoring.
Market Restraints
Funding and Skilled Workforce Shortages: Despite high demand, limited funding and a shortage of trained PV professionals constrain market expansion, particularly in regions like Africa. Insufficient resources delay reporting, monitoring, and compliance with regulations, impacting market effectiveness.
Market Segmentation
By Type: The services segment dominated with a 91.43% share in 2026, driven by clinical trials, outsourcing trends, and the demand for post-marketing surveillance. The software segment is the fastest-growing, supported by automation, AI, cloud platforms, and collaborations, such as Accenture's 2022 cloud-based IT platform for Astellas Pharma.
By Deployment: The outsourced segment led in 2026 with 57.03% share, enabling pharmaceutical companies to adapt to evolving regulations efficiently and reduce operational costs. In-house operations remain significant but face challenges due to limited expertise and resources.
By End-User: Pharmaceutical & biotechnology companies accounted for 62.51% of the market in 2026, leveraging PV services for regulatory compliance and safety monitoring of new drugs. CROs represent the second-largest end-user segment, providing cost-effective clinical trial and safety solutions to pharmaceutical companies.
Regional Insights
- North America: Valued at USD 3.82 billion in 2025, projected USD 4.32 billion in 2026; dominance due to regulatory stringency, advanced PV services, and a strong pharmaceutical industry.
- Europe: Steady growth; UK projected at USD 0.62 billion, Germany at USD 0.58 billion in 2026, supported by ADR awareness and mergers/acquisitions, such as ProPharma's acquisition of a European PV company.
- Asia Pacific: Fastest-growing region; Japan USD 0.42 billion, China USD 0.57 billion, India USD 0.42 billion in 2026, fueled by awareness, regulatory support, and expansion of global players.
- Latin America & Middle East & Africa: Moderate growth expected due to improved healthcare infrastructure, rising R&D, and expansion of PV service providers.
Key Industry Players
Leading companies include IQVIA Inc., Laboratory Corporation of America Holdings, Parexel International Corporation, Accenture, Cognizant, Ergomed Group, Thermo Fisher Scientific, ICON plc., and Quanticate. Strategic initiatives such as Ergomed's acquisition of Panacea (2024) and Accenture's AI-driven collaboration with Salesforce (2023) enhance market presence and service capabilities.
Conclusion
The global pharmacovigilance market is expected to grow from USD 9.35 billion in 2025 to USD 31.56 billion by 2034, driven by increasing ADR reporting, pharmaceutical outsourcing trends, AI adoption, and growing clinical trials. North America leads the market, while Asia Pacific exhibits the fastest growth. Services dominate due to outsourcing and clinical demand, and software adoption is rising rapidly with technological innovation. Strategic collaborations, AI-powered platforms, and public awareness campaigns will continue to fuel market expansion, ensuring improved drug safety, regulatory compliance, and public health outcomes globally.
Segmentation By Type
- Service
- Software
By Deployment
- In-house
- Outsource
By End User
- Contract Research Organizations (CROs)
- Pharmaceutical & Biotechnology Companies
- Others
By Region
- North America (By Type, Deployment, End-User, and Country)
- U.S. (By Type)
- Canada (By Type)
- Europe (By Type, Deployment, End-User, and Country/Sub-Region)
- Germany (By Type)
- U.K. (By Type)
- France (By Type)
- Italy (By Type)
- Spain (By Type)
- Rest of Europe (By Type)
- Asia Pacific (By Type, Deployment, End-User, and Country/Sub-Region)
- China (By Type)
- Japan (By Type)
- India (By Type)
- Australia (By Type)
- Southeast Asia (By Type)
- Rest of Asia Pacific (By Type)
- Latin America (By Type, Deployment, End-User, and Country/Sub-Region)
- Brazil (By Type)
- Mexico (By Type)
- Rest of Latin America (By Type)
- Middle East & Africa (By Type, Deployment, End-User, and Country/Sub-Region)
- GCC (By Type)
- South Africa (By Type)
- Rest of the Middle East & Africa (By Type)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Snapshot of Rate of Adverse Drug Reactions - By Key Region/Countries
- 4.2. Regulatory Scenario in the Pharmacovigilance Industry
- 4.3. Overview of Government Initiatives in Safe Medicine Use
- 4.4. Key Industry Developments (Mergers, Acquisitions, Collaborations, etc.)
- 4.5. Impact of COVID-19 on the Market
5. Global Pharmacovigilance Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Service
- 5.1.2. Software
- 5.2. Market Analysis, Insights and Forecast - By Deployment
- 5.2.1. In-house
- 5.2.2. Outsource
- 5.3. Market Analysis, Insights and Forecast - By End User
- 5.3.1. Contract Research Organizations (CROs)
- 5.3.2. Pharmaceutical & Biotechnology Companies
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America Pharmacovigilance Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Service
- 6.1.2. Software
- 6.2. Market Analysis, Insights and Forecast - By Deployment
- 6.2.1. In-house
- 6.2.2. Outsource
- 6.3. Market Analysis, Insights and Forecast - By End User
- 6.3.1. Contract Research Organizations (CROs)
- 6.3.2. Pharmaceutical & Biotechnology Companies
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.1.1. By Type
- 6.4.2. Canada
- 6.4.2.1. By Type
- 6.4.1. U.S.
7. Europe Pharmacovigilance Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Service
- 7.1.2. Software
- 7.2. Market Analysis, Insights and Forecast - By Deployment
- 7.2.1. In-house
- 7.2.2. Outsource
- 7.3. Market Analysis, Insights and Forecast - By End User
- 7.3.1. Contract Research Organizations (CROs)
- 7.3.2. Pharmaceutical & Biotechnology Companies
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.4.1. Germany
- 7.4.1.1. By Type
- 7.4.2. U.K.
- 7.4.2.1. By Type
- 7.4.3. France
- 7.4.3.1. By Type
- 7.4.4. Italy
- 7.4.4.1. By Type
- 7.4.5. Spain
- 7.4.5.1. By Type
- 7.4.6. Rest of Europe
- 7.4.6.1. By Type
- 7.4.1. Germany
8. Asia Pacific Pharmacovigilance Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Service
- 8.1.2. Software
- 8.2. Market Analysis, Insights and Forecast - By Deployment
- 8.2.1. In-house
- 8.2.2. Outsource
- 8.3. Market Analysis, Insights and Forecast - By End User
- 8.3.1. Contract Research Organizations (CROs)
- 8.3.2. Pharmaceutical & Biotechnology Companies
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.4.1. China
- 8.4.1.1. By Type
- 8.4.2. Japan
- 8.4.2.1. By Type
- 8.4.3. India
- 8.4.3.1. By Type
- 8.4.4. Australia
- 8.4.4.1. By Type
- 8.4.5. Southeast Asia
- 8.4.5.1. By Type
- 8.4.6. Rest of Asia Pacific
- 8.4.6.1. By Type
- 8.4.1. China
9. Latin America Pharmacovigilance Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Service
- 9.1.2. Software
- 9.2. Market Analysis, Insights and Forecast - By Deployment
- 9.2.1. In-house
- 9.2.2. Outsource
- 9.3. Market Analysis, Insights and Forecast - By End User
- 9.3.1. Contract Research Organizations (CROs)
- 9.3.2. Pharmaceutical & Biotechnology Companies
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.4.1. Brazil
- 9.4.1.1. By Type
- 9.4.2. Mexico
- 9.4.2.1. By Type
- 9.4.3. Rest of Latin America
- 9.4.3.1. By Type
- 9.4.1. Brazil
10. Middle East & Africa Pharmacovigilance Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Service
- 10.1.2. Software
- 10.2. Market Analysis, Insights and Forecast - By Deployment
- 10.2.1. In-house
- 10.2.2. Outsource
- 10.3. Market Analysis, Insights and Forecast - By End User
- 10.3.1. Contract Research Organizations (CROs)
- 10.3.2. Pharmaceutical & Biotechnology Companies
- 10.3.3. Others
- 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.4.1. GCC
- 10.4.1.1. By Type
- 10.4.2. South Africa
- 10.4.2.1. By Type
- 10.4.3. Rest of Middle East & Africa
- 10.4.3.1. By Type
- 10.4.1. GCC
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. IQVIA Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products & Services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Labcorp Drug Development
- 11.2.2.1. Overview
- 11.2.2.2. Products & Services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Parexel International Corporation
- 11.2.3.1. Overview
- 11.2.3.2. Products & Services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Accenture
- 11.2.4.1. Overview
- 11.2.4.2. Products & Services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Cognizant
- 11.2.5.1. Overview
- 11.2.5.2. Products & Services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Ergomed Group
- 11.2.6.1. Overview
- 11.2.6.2. Products & Services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Thermo Fisher Scientific Inc. (Pharmaceutical Product Development, LLC)
- 11.2.7.1. Overview
- 11.2.7.2. Products & Services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. ICON plc.
- 11.2.8.1. Overview
- 11.2.8.2. Products & Services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Quanticate
- 11.2.9.1. Overview
- 11.2.9.2. Products & Services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.1. IQVIA Inc.
List of Tables
- Table 01: Global Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 02: Global Pharmacovigilance Market Revenue (USD billion) Forecast, By Deployment, 2021-2034
- Table 03: Global Pharmacovigilance Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 04: Global Pharmacovigilance Market Revenue (USD billion) Forecast, By Region, 2021-2034
- Table 05: North America Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 06: North America Pharmacovigilance Market Revenue (USD billion) Forecast, By Deployment, 2021-2034
- Table 07: North America Pharmacovigilance Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 08: North America Pharmacovigilance Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 09: U.S. Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 10: Canada Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 11: Europe Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 12: Europe Pharmacovigilance Market Revenue (USD billion) Forecast, By Deployment, 2021-2034
- Table 13: Europe Pharmacovigilance Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 14: Europe Pharmacovigilance Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
- Table 15: Germany Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 16: U.K Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 17: France Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 18: Italy Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 19: Spain Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 20: Rest of Europe Pharmacovigilance Market Revenue (USD billion) Forecast, By Type,
- Table 21: Asia Pacific Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 22: Asia Pacific Pharmacovigilance Market Revenue (USD billion) Forecast, By Deployment, 2021-2034
- Table 23: Asia Pacific Pharmacovigilance Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 24: Asia Pacific Pharmacovigilance Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
- Table 25: China Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 26: Japan Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 27: India Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 28: Australia Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 29: Southeast Asia Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 30: Rest of Asia Pacific Pharmacovigilance Market Revenue (USD billion) Forecast, By
- Table 31: Latin America Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 32: Latin America Pharmacovigilance Market Revenue (USD billion) Forecast, By Deployment, 2021-2034
- Table 33: Latin America Pharmacovigilance Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 34: Latin America Pharmacovigilance Market Revenue (USD billion) Forecast, By
- Table 35: Brazil Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 36: Mexico Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 37: Rest of Latin America Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 38: Middle East & Africa Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 39: Middle East & Africa Pharmacovigilance Market Revenue (USD billion) Forecast, By Deployment, 2021-2034
- Table 40: Middle East & Africa Pharmacovigilance Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 41: Middle East & Africa Pharmacovigilance Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
- Table 42: GCC Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 43: South Africa Pharmacovigilance Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 44: Rest of Middle East & Africa Pharmacovigilance Market Revenue (USD billion)
List of Figures
- Figure 01: Global Pharmacovigilance Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
- Figure 02: Global Pharmacovigilance Market Value Share (%), By Type, 2025 & 2034
- Figure 03: Global Pharmacovigilance Market Value Share (%), By Deployment, 2025 & 2034
- Figure 04: Global Pharmacovigilance Market Value Share (%), By End User, 2025 & 2034
- Figure 05: Global Pharmacovigilance Market Value Share (%), By Region, 2025 & 2034
- Figure 06: North America Pharmacovigilance Market Value (USD billion), by Type, 2025 & 2034
- Figure 07: North America Pharmacovigilance Market Value Share (%), by Type, 2025
- Figure 08: North America Pharmacovigilance Market Value (USD billion), by Deployment, 2025 & 2034
- Figure 09: North America Pharmacovigilance Market Value Share (%), by Deployment, 2025
- Figure 10: North America Pharmacovigilance Market Value (USD billion), by End User, 2025 & 2034
- Figure 11: North America Pharmacovigilance Market Value Share (%), by End User, 2025
- Figure 12: North America Pharmacovigilance Market Value (USD billion), By Country, 2025 & 2034
- Figure 13: North America Pharmacovigilance Market Value Share (%), By Country, 2025
- Figure 14: Europe Pharmacovigilance Market Value (USD billion), by Type, 2025 & 2034
- Figure 15: Europe Pharmacovigilance Market Value Share (%), by Type, 2025
- Figure 16: Europe Pharmacovigilance Market Value (USD billion), by Deployment, 2025 & 2034
- Figure 17: Europe Pharmacovigilance Market Value Share (%), by Deployment, 2025
- Figure 18: Europe Pharmacovigilance Market Value (USD billion), by End User, 2025 & 2034
- Figure 19: Europe Pharmacovigilance Market Value Share (%), by End User, 2025
- Figure 20: Europe Pharmacovigilance Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
- Figure 21: Europe Pharmacovigilance Market Value Share (%), By Country/Sub-Region, 2025
- Figure 22: Asia Pacific Pharmacovigilance Market Value (USD billion), by Type, 2025 & 2034
- Figure 23: Asia Pacific Pharmacovigilance Market Value Share (%), by Type, 2025
- Figure 24: Asia Pacific Pharmacovigilance Market Value (USD billion), by Deployment, 2025 & 2034
- Figure 25: Asia Pacific Pharmacovigilance Market Value Share (%), by Deployment, 2025
- Figure 26: Asia Pacific Pharmacovigilance Market Value (USD billion), by End User, 2025 & 2034
- Figure 27: Asia Pacific Pharmacovigilance Market Value Share (%), by End User, 2025
- Figure 28: Asia Pacific Pharmacovigilance Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
- Figure 29: Asia Pacific Pharmacovigilance Market Value Share (%), By Country/Sub-Region, 2025
- Figure 30: Latin America Pharmacovigilance Market Value (USD billion), by Type, 2025 & 2034
- Figure 31: Latin America Pharmacovigilance Market Value Share (%), by Type, 2025
- Figure 32: Latin America Pharmacovigilance Market Value (USD billion), by Deployment, 2025 & 2034
- Figure 33: Latin America Pharmacovigilance Market Value Share (%), by Deployment, 2025
- Figure 34: Latin America Pharmacovigilance Market Value (USD billion), by End User, 2025 & 2034
- Figure 35: Latin America Pharmacovigilance Market Value Share (%), by End User, 2025
- Figure 36: Latin America Pharmacovigilance Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
- Figure 37: Latin America Pharmacovigilance Market Value Share (%), By Country/Sub-Region, 2025
- Figure 38: Middle East & Africa Pharmacovigilance Market Value (USD billion), by Type, 2025 & 2034
- Figure 39: Middle East & Africa Pharmacovigilance Market Value Share (%), by Type, 2025
- Figure 40: Middle East & Africa Pharmacovigilance Market Value (USD billion), by Deployment, 2025 &2034
- Figure 41: Middle East & Africa Pharmacovigilance Market Value Share (%), by Deployment 2025
- Figure 42: Middle East & Africa Pharmacovigilance Market Value (USD billion), by End User, 2025 & 2034
- Figure 43: Middle East & Africa Pharmacovigilance Market Value Share (%), by End User, 2025
- Figure 44: Middle East & Africa Pharmacovigilance Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
- Figure 45: Middle East & Africa Pharmacovigilance Market Value Share (%), By Country/Sub-Region, 2025
- Figure 46: Global Pharmacovigilance Market Share (%), By Company, 2025
